The Administration’s recently released final rule on transparency in healthcare coverage is set to take effect January 1, 2023. The rule aims to provide increased visibility into the cost of care for treatments and procedures and to support cost-conscious decisions about healthcare services. Precision’s Erin Lopata provides an overview of what you need to know now.
Update on HHS drug pricing rules: An HHS final rule targeting Medicare Part D rebates was issued on November 30, 2020. Unlike the interim rule, the final rule includes only rebates in Part D, not Medicaid managed care, and it pushes back implementation from Jan. 1, 2020, to Jan. 1, 2022. Comments on the interim final rule following the Most Favored Nation model are due by Jan. 26, 2021. Precision’s Andrew Cournoyer and Ryan Cox weigh in on the problems and concerns with both rules.
The COVID-19 pandemic consumed most of 2020. While it was the big story last year, it wasn’t the only story. Precision’s Dan Danielson and other experts weigh in on the oversized impact of COVID-19 on the pharma industry, and other trends from 2020.
Value-based care has been replacing the traditional fee-for-service model in the United States. Value-based care models and population health are essential to improving health and reducing health care costs. Precision’s Ryan Cox discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patients.
While the development and introduction of new pharmaceuticals have played a pivotal role in reducing US cancer deaths, winning the war on cancer is a multifaceted battle. Meanwhile, COVID-19 has affected virtually every aspect of cancer care, from the research and development of new therapies, to diagnosis and treatment.
An interim final rule that would require pricing drugs on the U.S. market based on their prices in certain countries is set to take effect on Jan. 1, 2021. Industry experts claim it will have little effect on bringing down prices for consumers. Precision’s Ryan Cox joins other experts in discussing the far ranging impact of the new rule.
Research suggests that new cancer treatments have played an especially important role in reducing mortality rates in certain cancers over the past several decades. Disruption to the industry from the COVID-19 pandemic threatens this progress.
In an effort to increase patient access to affordable drugs, California recently created Cal Rx, a state-sponsored generic prescription drug label. Precision’s Jason Shafrin weighs in on the potential impact the law ultimately will have.
Today, marketers in pharma are not only tasked with optimizing the usual suspects in their marketing technology (martech) stack. They must also consider emerging technologies, those as-yet-proven tools and approaches that show promise in boosting brand strategies and strengthening connections with HCPs. Precision’s Marty Samples identifies four key tech trends to focus on to grow engagement with healthcare professionals in 2021 and beyond.
Many highly specialized, expensive drugs are in protected categories that must be covered. With few other options, payers are digging in with more prior authorization and other utilization management tactics. Precision’s Dominic Galante weighs in on the increasingly difficult path to securing prior payer approval for high cost drugs.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
